Please login to the form below

Not currently logged in
Email:
Password:

research costs

This page shows the latest research costs news and features for those working in and with pharma, biotech and healthcare.

Keytruda growth helps Merck to offset COVID-19 impact in Q3

Keytruda growth helps Merck to offset COVID-19 impact in Q3

On the expenses front, research and development costs were up by 6% to $3.4bn in the quarter, as a result of an increase in upfront payments related to collaborations and ... On top of that, expenses related to clinical development and investments in

Latest news

  • Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

    Eli Lilly third quarter earnings missed analyst expectations as a result of increased pressure on pricing for its top drugs, as well as climbing development costs for its COVID-19 clinical ... This was due to increasing research and development costs,

  • Key emerging trends in digital health Key emerging trends in digital health

    A major issue facing the pharmaceutical industry is the growing costs of research and development of new drugs, with clinical trials shouldering much of that expense. ... For the life sciences industry, tackling high dropout rates, along with encouraging

  • Avenir acquires Cherry, EY wins new account and GK unites businesses Avenir acquires Cherry, EY wins new account and GK unites businesses

    The tech could potentially improve patient outcomes, reduce healthcare costs and accelerate medical research, and the new agreement with EY will allow Sensyne to further scale up its business, including responding ... Unlocking the power within

  • NHS England pledges to streamline clinical trial setup NHS England pledges to streamline clinical trial setup

    The process will also target the procedure for reimbursements in additional treatment costs. ... The new processes will also try to simplify and speed up the process for reimbursements for excess treatment costs in non-commercial research, says NHS

  • Profit: the ugly, dirty truth? Profit: the ugly, dirty truth?

    The absence of a sustainable market-place to mitigate risk in research and development costs explains why so many global players have left the field. ... It’s not a recipe for delivering the vast investment into antibiotics research that is needed.

More from news
Approximately 0 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • The 2019 CPhI Pharma Index Report The 2019 CPhI Pharma Index Report

    Competitiveness. The industry experts assessed each market’s competitiveness on a variety of factors including the country’s labour costs, quality of skilled labour, research potential and tax environment.

  • The Golden Goose The Golden Goose

    to make enough money in aggregate [emphasis added] to cover initial research costs.but [this] leads manufacturers to price discriminate across markets and may lead to a sense that some markets ... Haislmaier, senior research fellow at the Heritage

  • Cost containment and the German market Cost containment and the German market

    The country provides a growing healthcare market for manufacturers, with a good infrastructure, qualified employees and a number of research institutions enabling a productive knowledge exchange. ... Innovative medicine requires high research and

  • Applying real-world evidence to orphan drugs Applying real-world evidence to orphan drugs

    However, for many rare disease therapies, the research and development (R&D) costs far outweigh the expected revenue once the product is launched. ... In Europe, the EU Committee of Experts on Rare Diseases (EUCERD) and the European Platform for Rare

  • The Maverick: giving medicines away free The Maverick: giving medicines away free

    Why patent it, when it won't work on anyone else?”. He says this model also cuts down on research and development costs, which he claims could be reduced to just ... This would also drastically reduce manufacturing costs. He also wants other

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Is agile working benefiting the employee or the organisation?

    Beyond reduced office costs, research tells us that agile working improves morale, increases staff retention and importantly widens and unlocks a bigger talent pool.  . ... In this blog Angela draws on her experience and reflects on how the development

  • AskMED.co.uk

    AskMED brings medical professionals together online to provide rapid analysis and feedback for industry questions at a fraction of traditional research costs.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics